In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms

Human and Experimental Toxicology

Volumn 19, Issue 3, 2000, Pages 178-184

  Abbas, R ^a   Chow, C P ^b   Browder, N J ^a   Thacker, D ^c   Bramer, S L ^a   Fu, C J ^d   Forbes, W ^a   Odomi, M ^e   Flockhart, D A ^c  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b PURDUE PHARMA L P   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d Kansas City Analytical Services   (United States)

^e OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cilostazol; CYP450; In vitro; Interaction; Isoforms; Metabolism

Indexed keywords

6 [4 (1 CYCLOHEXYL 1H TETRAZOL 5 YL)BUTOXY] 3,4 DIHYDRO 4 HYDROXY 2(1H) QUINOLINONE; CILOSTAZOL; CIMETIDINE; CYTOCHROME P450; CYTOCHROME P450 3A; DEBRISOQUINE 4 HYDROXYLASE; FELODIPINE; KETOCONAZOLE; OMEPRAZOLE; PHENACETIN O DEETHYLASE; QUINIDINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; MICHAELIS CONSTANT; PRIORITY JOURNAL;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0034092579     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032700678827717     Document Type: Article

References (12)

1. Akiyama H, Kudo S, Shimizu T. The metabolism of a new antithrombotic and vasodilating agent, cilostazol in rat, dog and man. Arzneimittelforschung 1985; 35: 1133-1140.
2. Harris JW et al. Metabolism by taxol and human hepatic microsomes and liver slices: Participation of Cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994; 54: 4026-4035.
3. Pollard HB et al. Application of Bradford's protein assay to adrenal gland subcellular fractions. Anal Biochem 1978; 86: 761-763.
4. Tata PNV et al. The quantitative determination of Cilostazol and four metabolites in human liver microsomal incubation mixture by High Performance Liquid Chromatography. J Pharmaceutical and Biomedical Analysis 1998; 18: 441-451.
5. Ko et al. Evaluation of Omeprazole and Lansoprazole as inhibitors of Cytochrome P450 isoforms. Drug Metab Dispos 1997; 25, 853-862.
6. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LA, Gelboin HV, Miners JO. Specificity of substrate probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993; 265, 401-407.
7. Sesardic et al. Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. Br J Clin Pharm 1990; 29, 651-663.
8. Miners JO, Veronese ME, Birkett, DJ. In Vitro Approaches for the Prediction of Human Drug Metabolism 1994; 29: 307-316 (Abstract).
9. Ortiz de Montellano PR et al. Selective inactivation of cytochrome P450 isoenzymes by suicide substrates. Arch Biochem Biophys 1981; 210: 717-728.
10. Larrey D, Funck-Brentano C, Breil P. Effects of erythromycin on Hepatic Drug-Metabolizing Enzymes in Humans. Biochem Pharmacol 1982; 32, 1063-1068.
11. Shimada T et al. Interindividual variations in human liver Cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Pharmacol Exp Ther 1994; 270: 414-423.
12. Baldwin SJ et al. KetoconazoJe and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261-270.